GlaxoSmithKline Finds High Efficacy Rate in Study of Two-Drug HIV Regimen

By Adriano Marchese

GlaxoSmithKline PLC (GSK.LN) said Wednesday that a study found high efficacy rates and no cases of treatment emergent resistance for its two HIV drugs, Dolutegravir and Lamivudine.

ViiV Healthcare, of which GlaxoSmithKline is a majority shareholder, said that week 96 data from the GEMINI studies demonstrate that the clinical benefits of Dolutegravir plus Lamivudine at week 48 are sustainable. It also said that the findings provide further evidence of the benefits of two-drug regimen.

"These latest findings are important for people living with HIV who will potentially spend decades taking medication to manage their HIV," Principal Investigator for the GEMINI study program, Pedro Cahn, said.

Write to Adriano Marchese at adriano.marchese@dowjones.com

(END) Dow Jones Newswires

July 24, 2019 11:47 ET (15:47 GMT)

GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024